Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.21 - $59.36 $1.07 Million - $1.58 Million
26,600 New
26,600 $1.48 Million
Q1 2022

May 17, 2022

BUY
$62.2 - $84.4 $230,140 - $312,280
3,700 Added 22.42%
20,200 $1.47 Million
Q3 2021

Nov 16, 2021

BUY
$77.92 - $102.4 $109,088 - $143,360
1,400 Added 9.27%
16,500 $1.49 Million
Q1 2021

May 18, 2021

SELL
$106.9 - $167.73 $448,980 - $704,466
-4,200 Reduced 21.76%
15,100 $1.72 Million
Q4 2020

Feb 17, 2021

SELL
$84.4 - $177.39 $75,960 - $159,651
-900 Reduced 4.46%
19,300 $2.67 Million
Q3 2020

Nov 17, 2020

BUY
$72.98 - $90.0 $576,542 - $711,000
7,900 Added 64.23%
20,200 $1.66 Million
Q2 2020

Aug 17, 2020

BUY
$46.91 - $78.22 $576,993 - $962,106
12,300 New
12,300 $962,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.